SCHEMBL268053

SCHEMBL268053

COc1cc(OC)cc(C(=O)Nc2ccccc2C(=O)N/N=C/c2ccc(OC)c(Br)c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.66
MAPT P10636 8/20 0.66
HPGD P15428 7/20 0.66
KMT2A Q03164 5/20 0.66
PKM P14618 4/20 0.66
MEN1 O00255 4/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
ALOX12 P18054 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66
NPC1 O15118 6/20 0.59
RAB9A P51151 5/20 0.59
ALDH1A1 P00352 6/20 0.58
TSHR P16473 1/20 0.56
HSD17B10 Q99714 1/20 0.56
OPRK1 P41145 1/20 0.56
HTT P42858 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
POLB P06746 1/20 0.54
LMNA P02545 2/20 0.52
DNM1 Q05193 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268054 1.00 KDM4E (0.66) KDM4EMAPTHPGDKMT2APKM
SCHEMBL268714 0.92 MAPT (0.78) KDM4EMAPTHPGDKMT2APKM
SCHEMBL268715 0.92 MAPT (0.78) KDM4EMAPTHPGDKMT2APKM
SCHEMBL269230 0.89 NPC1 (0.74) KDM4EMAPTHPGDKMT2APKM
SCHEMBL269229 0.89 NPC1 (0.74) KDM4EMAPTHPGDKMT2APKM
SCHEMBL267106 0.88 KMT2A (0.65) KDM4EMAPTHPGDKMT2APKM
SCHEMBL267105 0.88 KMT2A (0.65) KDM4EMAPTHPGDKMT2APKM
SCHEMBL265193 0.86 NPC1 (0.59) KDM4EMAPTHPGDKMT2APKM
SCHEMBL265194 0.86 NPC1 (0.59) KDM4EMAPTHPGDKMT2APKM
SCHEMBL267771 0.85 KDM4E (0.64) KDM4EMAPTHPGDKMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KDM4E 4468/4885MAPT 4195/4885HPGD 2509/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KDM4E 4535/4885MAPT 4648/4885HPGD 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.